Both the TGFβ1 neutralizing antibody (1μg/ml) and SB431542 abolished smad2 nuclear localization, implying that PSC-derived TGFβ1 activated smad2 signaling in tumor cells (Figure 6H). This evidence concerns the gene SMAD2 and neoplasm.